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Summary
Randomization is a common technique used in clinical trials to eliminate potential
bias and confounders in a patient population. Equal allocation to treatment groups
is the standard due to its optimal efficiency in many cases. However, in certain sce-
narios, unequal allocation can improve efficiency. In superiority trials with more
than two groups, the optimal randomization is not always a balanced randomiza-
tion. In non-inferiority trials, additive margin with equal variance is the only instance
with balanced randomization. Optimal randomization for non-inferiority trials can
be far from 1:1 and can greatly improve efficiency, a fact which is commonly over-
looked. A tool for sample size calculation for non-inferiority trials with additive or
multiplicative margin with normal, binomial or Poisson distribution is available at
http://www.statlab.wisc.edu/shiny/SSNI/.
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1 INTRODUCTION
Randomization remains a gold standard method in clinical trial methodology to eliminate potential bias and confounders. Ran-
domization eliminates a systematic difference between subjects in treatment groups inducing approximate balance with respect
to covariates, both observed and unobserved. Equal allocation to treatment groups is the standard due to its high efficiency in
many cases. Statistical efficiencies are directly related to statistical power. Thus, increasing statistical efficiencies improves the
likelihood of correctly rejecting the null hypothesis when the alternative is true.
However, the ethics of imbalanced randomization is highly debated. Unbalanced randomization is suggested to have an ethical
advantage over balanced design due to the facts that more subjects are assigned to the new treatment than the control treatment
and the new treatment is assumed to be superior1. However, there is a growing trend in trials with imbalanced treatment alloca-
tion2. Avins argue that if the chances of success higher with a new intervention, randomizing a greater proportion of subjects
to the new intervention is highly desirable3. Pocock also asserts that there is a little loss in power with a moderate unbalanced
randomization scheme3,4. On the other hand, Edwards et al. argue that even though, unbalanced randomization might increase
recruitment in a trial, the patient’s expected benefit of a treatment might increase due to the notion of an increased chance of
getting their preferred treatment5. Unbalanced randomization in a clinical trial might seem to be a favorable design due to sev-
eral constraints such as limitation of available resources, increase chances of attaining required sample size and testing the side
effects of a new treatment/drug.
In certain trials, limitation of resources tends to hinder the success of a trial. Thus, investigators tend to reduce the patient
allocation in the scarce group to overcome this issue. For instance, in the CPORT trial, if the availability of on-site cardiac
surgery is a scarce resource, then the study could randomize more patients to the group of off-site cardiac surgery to overcome
0Abbreviations: NI, non-inferiority; ARE, asymptotic relative efficiency; CPORT, Cardiovascular Patient Outcomes Research Team; CI, confidence interval
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2 CHANDERENG ET AL
this issue. However, this was not the real reason behind the choice of 3:1 randomization in the CPORT study. Patients were
randomized 3:1 to provide sufficient training to surgeons. On the other hand, the cost can also contribute to the imbalance in a
trial2. Imbalanced allocation of patients might be beneficial to reduce the overall cost of a trial. Compared to inefficient trial, in
an efficient trial, fewer patients are required to be recruited in a trial to attain the appropriate statistical power.
Patients tend to be frustrated with equal allocation trials of a deadly disease due to the low chances of getting the new
treatment6. Thus, imbalanced trials tend to attract more patients due to a higher tendency of getting a new treatment. However,
imbalance could reduce the statistical power and increase the sample size required2. Even though early phase trials are designed
to study the efficacy of dosage of new treatment, these trials are conducted in a small sample and they fail to capture the complete
effect of a treatment. Thus, imbalanced trials favoring an experimental treatment might be helpful to further analyze its side
effects.
After briefly looking at the optimal randomization ratio for multiple doses against control in superiority trials, we provide
a quick introduction to non-inferiority trials. Then, we move on to the optimal allocation in a non-inferiority trials with equal
and unequal variance and additive and multiplicative non-inferiority margins. We also derive the optimal randomization ratio
for the number of events required for survival data in a non-inferiority trial before moving on to use the Cardiovascular Patient
Outcomes Research Team (CPORT) study of percutaneous revascularization as an example.
2 "ALL-DOSES-AGAINST-CONTROL" IN SUPERIORITY TRIALS
Dunnett’s paper on comparing several treatments to a control illustrates the low efficiency of assigning all treatments equally for
comparing multiple treatments to a control, but not to each other7. However, the paper did not provide a closed-form solution7.
This is derived here.
2.1 Equal variance
Consider a superiority trial in which multiple experimental treatments (often different doses of the same drug) are compared to
a control, with total sample size N and mean outcomes 휇푖, where 푖 indexes group, and constant variance 휎2. There are a total of
푘 groups, where Group 1 is the control dose and the other 푘−1 groups are the experimental doses, and we want to compare the
experimental groups to the control but not to each other. The 푘−1 null hypotheses are as follows, with alternatives of inequality.
Our goal is to maximize their common power.
퐻0,1 ∶ 휇2 = 휇1,
퐻0,2 ∶ 휇3 = 휇1,
⋮
퐻0,푘−1 ∶ 휇푘 = 휇1.
Denote the sample size allocated in the control group 푐푁 , so that every other group is allocated 푁(1−푐)
푘−1
. In order to compute
the optimal 푐, we minimize the total variance below with respect to 푐 (0 < 푐 < 1).
푘∑
푖=2
푉 푎푟(푋̄푖 − 푋̄1) ∝
푘 − 1
1 − 푐
+ 1
푐
휕
∑푘
푖=2 푉 푎푟(푋̄푖 − 푋̄1)
휕푐
∝ −1
푐2
+ 푘 − 1
(1 − 푐)2
= 0.
푐 =
⎧⎪⎨⎪⎩
1
2
, if k = 2
−1 +
√
푘 − 1
푘 − 2
, if k > 2.
The asymptotic relative efficiency (ARE) of the optimal allocation (A1) relative to equal allocation (A2) is
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퐴푅퐸(퐴1, 퐴2) = 2푘(푘 − 1)
(
√
푘 − 1 + 푘 − 1)2
> 1, for 푘 > 2.
2.2 Unequal variance
If each of the dosage groups has a different variance, this becomes a harder optimization problem. Denote the variance of group
푖 by 휎2푖 . The sample size allocated to each group is 푐푖푁 for group 푖 where 1 ≤ 푖 ≤ 푘 (0 < 푐푖 < 1, ∑푘푖=1 푐푖 = 1). The objectivefunction is
푘∑
푖=2
푉 푎푟(푋̄푖 − 푋̄1) ∝
(푘 − 1)휎21
푐1
+
휎22
푐2
+ ... +
휎2푘
푐푘
.
The optimal solution for the 푐1, ..., 푐푘−1 is
푐1 =
휎1
√
푘 − 1
휎1
√
푘 − 1 +
∑푘
푖=2 휎푖
, 푐ℎ =
휎ℎ
휎1
√
푘 − 1 +
∑푘
푖=2 휎푖
for ℎ ≥ 2.
The asymptotic relative efficiency of the optimal allocation (A1) relative to equal allocation (A2) is
퐴푅퐸(퐴1, 퐴2) =
푘(푘 − 1)휎21 + 푘
∑푘
푖=2 휎
2
푖
(휎1
√
푘 − 1 +
∑푘
푖=2 휎푖)2
> 1 for 푘 > 2.
3 EFFICIENCY VS. RANDOMIZATION RATIO IN NON-INFERIORITY TRIALS WITH
TWO TREATMENTS
3.1 Non-inferiority trials
Non-inferiority trials are clinical trials designed to establish that a new treatment is not that much worse than a standard control8.
Thus, a new treatment can be favorable even if it is slightly worse than the current treatment. Unlike equivalence trials, non-
inferiority trials do allow the possibility of the new treatment being better than the standard treatment9. The new treatment is
believed to offer ancillary benefit in terms of side effects, safety or other factors. Outcomes are not always efficacy.
A margin is introduced to allow a small loss in effect by the new treatment compared to the control treatment. This margin
serves as a maximum acceptable threshold and determined in advance.10,11. Factors such as historical data and physician’s
experience play a vital role in the decision of setting a margin for a non-inferiority trial. The selection of margin scale used
(difference in means of two groups, ratios of means, etc.) is less commonly stated but is important for computing sample sizes
and interpretation of results12.
DenoteΔ > 0 for an additivemargin andΔ > 1 for amultiplicativemargin. The corresponding non-inferiority trial hypotheses
for an additive margin to test the difference in means are
퐻0 ∶ 휇퐶 − 휇푇 ≥ Δ
퐻퐴 ∶ 휇퐶 − 휇푇 < Δ
where 휇퐶 is the mean of the control group and 휇푇 is the mean of the experimental group. On the other hand, the corresponding
non-inferiority trial hypotheses for a multiplicative margin to test the differences in means are
퐻0 ∶
휇퐶
휇푇
≥ Δ
퐻퐴 ∶
휇퐶
휇푇
< Δ
where 휇퐶 is the mean of the control group and 휇푇 is the mean of the experimental group. Higher means are considered favorable.
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3.2 Imbalance in non-inferiority trials: equal variance
The optimal allocation for different scenarios are computed below. The variance for the both the treatment and control groups
is denoted by 휎2.
3.2.1 Optimal allocation for additive Δ
퐻0 ∶ 휇퐶 − 휇푇 ≥ Δ.
In this case, the optimal randomization ratio is 1:1 since 푉 푎푟(푋̄퐶 ) = 푉 푎푟(푋̄푇 ) .
3.2.2 Optimal allocation for multiplicative Δ
퐻0 ∶
휇퐶
휇푇
≥ Δ.
The optimal sample size allocated in the control group is denoted ℎ푁 and every other group is allocated (1-ℎ)푁 . In order to
compute the optimal ℎ, we minimize the variance below with respect to ℎ, (0 < ℎ < 1).
푉 푎푟(푋̄푇 − Δ푋̄퐶 ) ∝
1
ℎ
+ Δ2 1
1 − ℎ
휕푉 푎푟(푋̄푇 − Δ푋̄퐶 )
휕ℎ
∝ −1
ℎ2
+ Δ2 1
(1 − ℎ)2
= 0
ℎ = 1
Δ + 1
.
The asymptotic relative efficiency of the optimal allocation (A1) relative to equal allocation (A2) is
퐴푅퐸(퐴1, 퐴2) =
2(1 + Δ2)
(Δ + 1)2
≥ 1.
3.3 Imbalance in non-inferiority trial: unequal variance
The variance in the treatment groups are not equal, for example with binomial or Poisson outcomes. The variance is denoted by
휎2푖 = 푉 (휇푖), 푉 (휇푖) is the variance of treatment 푖 and it is a function of 휇푖.
3.3.1 Optimal allocation for additive Δ
퐻0 ∶ 휇퐶 − 휇푇 ≥ Δ.
The optimal sample size allocated in the control group is denoted ℎ푁 and every other group is allocated (1-ℎ)푁 . In order to
compute the optimal ℎ, we minimize the variance below with respect to ℎ, (0 < ℎ < 1).
푉 푎푟(푋̄퐶 − 푋̄푇 − Δ) ∝
휎2퐶
ℎ
+
휎2푇
1 − ℎ
휕푉 푎푟(푋̄퐶 − 푋̄푇 − Δ)
휕ℎ
∝
−휎2퐶
ℎ2
+
휎2푇
(1 − ℎ)2
= 0
ℎ =
휎퐶
휎퐶 + 휎푇
.
The asymptotic relative efficiency of the optimal allocation (A1) relative to equal allocation (A2) is
퐴푅퐸(퐴1, 퐴2) =
2(휎2퐶 + 휎
2
푇 )
(휎퐶 + 휎푇 )2
≥ 1.
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3.3.2 Optimal allocation for multiplicative Δ
퐻0 ∶
휇퐶
휇푇
≥ Δ.
The optimal sample size allocated in the control group is denoted ℎ푁 and every other group is allocated (1-ℎ)푁 . In order to
compute the optimal ℎ, we minimize the variance below with respect to ℎ, (0 < ℎ < 1).
푉 푎푟(푋̄퐶 − Δ푋̄푇 ) ∝
휎2퐶
ℎ
+ Δ2
휎2푇
1 − ℎ
휕푉 푎푟(푋̄퐶 − Δ푋̄푇 )
휕ℎ
∝
−휎2퐶
ℎ2
+ Δ2
휎2푇
(1 − ℎ)2
= 0
ℎ =
휎퐶
휎퐶 + Δ휎푇
.
The asymptotic relative efficiency of the optimal allocation (A1) relative to equal allocation (A2) is
퐴푅퐸(퐴1, 퐴2) =
2(휎2퐶 + Δ
2휎2푇 )
(휎퐶 + Δ휎푇 )2
≥ 1.
3.4 The general case for generalized linear models
The derivation for binomial and Poisson null hypothesis are illustrated below. In the binomial case, consider 휋퐶 and 휋푇 as the
probability of success for control and treatment group. Meanwhile, in the Poisson group consider 휆퐶 and 휆푇 as the mean of
control and treatment group respectively.
The optimal sample size allocated in the control group is denoted ℎ푁 and every other group is allocated (1-ℎ)푁 . In order to
compute the optimal ℎ, we minimize the variance below with respect to ℎ, (0 < ℎ < 1).
3.4.1 Additive hypothesis
Binomial
퐻0 ∶ 휋퐶 − 휋푇 ≥ Δ.
ℎ =
√
휋퐶 (1 − 휋퐶 )√
휋퐶 (1 − 휋퐶 ) +
√
휋푇 (1 − 휋푇 )
.
The asymptotic relative efficiency of the optimal
allocation (A1) relative to equal allocation (A2) is
퐴푅퐸(퐴1, 퐴2) =
2(휋퐶 (1 − 휋퐶 ) + 휋푇 (1 − 휋푇 ))
(
√
휋푐(1 − 휋퐶 ) +
√
휋푇 (1 − 휋푇 ))2
≥ 1.
Poisson
퐻0 ∶ 휆퐶 − 휆푇 ≥ Δ.
ℎ =
√
휆퐶√
휆퐶 +
√
휆푇
.
The asymptotic relative efficiency of the optimal allocation
(A1) relative to equal allocation (A2) is
퐴푅퐸(퐴1, 퐴2) =
2(휆퐶 + 휆푇 )
(
√
휆퐶 +
√
휆푇 )2
≥ 1.
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3.4.2 Multiplicative hypothesis
Binomial
퐻0 ∶
휋퐶
휋푇
≥ Δ.
ℎ =
√
휋퐶 (1 − 휋퐶 )√
휋퐶 (1 − 휋퐶 ) + Δ
√
휋푇 (1 − 휋푇 )
.
The asymptotic relative efficiency of the optimal allocation
(A1) relative to equal allocation (A2) is
퐴푅퐸(퐴1, 퐴2) =
2(휋퐶 (1 − 휋퐶 ) + Δ2휋푇 (1 − 휋푇 ))
(
√
휋푐(1 − 휋퐶 ) + Δ
√
휋푇 (1 − 휋푇 ))2
≥ 1.
Poisson
퐻0 ∶
휆퐶
휆푇
≥ Δ.
ℎ =
√
휆퐶√
휆퐶 + Δ
√
휆푇
.
The asymptotic relative efficiency of the optimal allocation (A1)
relative to equal allocation (A2) is
퐴푅퐸(퐴1, 퐴2) =
2(휆퐶 + Δ2휆푇 )
(
√
휆퐶 + Δ
√
휆푇 )2
≥ 1.
3.5 Survival analysis
In clinical trials of outcomes which are times to events and therefore subject to events and therefore subject to censoring sample
size and efficiency depend on the number of events observed in each group. We adopted the number of events required in the
section below for two sample log-rank non-inferiority trials using proportional hazards assumption13. The hazard function for
the control treatment is denoted by 휆퐶 and the hazard function for the treatment group is denoted by 휆푇 . Under the proportional
hazards assumption, Δ = 휆푇 (푡)
휆퐶 (푡)
denotes the hazard ratio and usually the non-inferiority margin is set to Δ > 1.
We obtained the derivation of the number of events required, D from Jung et al. (2005)13. The test statistics is denoted by
퐻0 ∶ Δ ≥ Δ0 퐻퐴 ∶ Δ < Δ0.
Denote, 푝푁 is the sample size allocated in the control group and (1 − 푝)푁 the sample size allocated in the treatment group. 훼
and 1 − 훽 corresponds to the respective type I error rate and power for the clinical study.
퐷 =
{
√
Δ0푧1−훼 + (푝 + (1 − 푝)Δ0)푧1−훽)}2
푝(1 − 푝)(Δ0 − 1)2
By substituting 푎 =√Δ0푧1−훼 , 푏 = Δ0, 푐 = 푧1−훽 and 푑 = (Δ0 − 1)2, we get
퐷 = {푎 + (푝 + (1 − 푝)푏)푐)}
2
푝(1 − 푝)푑
; 0 > 푝 > 1
휕퐷
휕푝
∝ 2(푎 + 푏푐 − 푏푐푝 + 푐푝)(푐 − 푏푐)(1 − 푝)푝푑 − (푎 + 푏푐 − 푏푐푝 + 푝푐)2((1 − 2푝)푑)
∝ 2푐(푎 + 푏푐 − 푏푐푝 + 푐푝)(1 − 푏)(1 − 푝)푝 − (푎 + 푏푐 − 푏푐푝 + 푝푐)2(1 − 2푝)
= (푎 + 푏푐 − 푏푐푝 + 푐푝)(2푐푝(1 − 푏)(1 − 푝) − (푎 + 푏푐 − 푏푐푝 + 푝푐)(1 − 2푝))
= (푎 + 푏푐 − 푏푐푝 + 푐푝)(푐푝 − 푎 − 푏푐 + 푏푐푝 + 2푎푝).
Setting 휕퐷
휕푝
= 0 to obtain the minimum and replacing a, b and c respectively, we get
푝 =
⎧⎪⎪⎨⎪⎪⎩
√
Δ0푧1−훼 + Δ0푧1−훽
(Δ0 + 1)푧1−훽 + 2
√
Δ0푧1−훼√
Δ0푧1−훼 + Δ0푧1−훽
푧1−훽(Δ0 − 1)
.
Since 0 < 푝 < 1, the optimal solution for 푝, 푝 =
√
Δ0푧1−훼+Δ0푧1−훽
(Δ0+1)푧1−훽+2
√
Δ0푧1−훼
. The other solution of 푝 provides a value of greater than
1 when Δ0 > 1. The only instance with balanced randomization is when Δ0 = 1. However, this would not usually occur in a
non-inferiority trial design. Chow et al. (2017) provides a derivation for number of events required where the assumuption of
푆퐶 (푡) ≈ 푆푇 (푡) is made14. Due to the assumption, the optimal solution is 푝, 푝 = 0.5 always as shown in the derivation below.
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퐷 =
(푧1−훼 + 푧1−훽)2
푝(1 − 푝)(푙표푔Δ0)2
휕퐷
휕푝
∝
−((1 − 푝)(푙표푔Δ0)2 − 푝(푙표푔Δ0)2)
(푝(1 − 푝)(푙표푔Δ0)2)2
=
(2푝 − 1)(푙표푔Δ0)2
(푝(1 − 푝)(푙표푔Δ0)2)2
.
Setting the numerator of 휕퐷
휕푝
= 0, we always get 푝 = 0.5.
4 EXAMPLE: CPORT
The Cardiovascular Patient Outcomes Research Team (CPORT) study provides a motivating example for the current work. In
the CPORT study, physicians were interested in comparing the performance of percutaneous coronary intervention (PCI) at
hospitals with vs. without on-site cardiac surgery15. PCI is often restricted to hospitals with on-site cardiac surgery which limits
patients availability to receive the treatment. Based on previous studies, the six weeks (all-cause) rate of mortality was estimated
to be 0.8%. Therefore, the CPORT research tem was interested to show that 휋푇 − 휋퐶 < 0.004
CPORT was a multi-center randomized trial with 18,867 patients who were randomized at 3:1 in the control group to undergo
PCI with 14,149 patients undergoing PCI at a hospital without on-site cardiac surgery and 4,718 patients undergoing PCI at
hospitals with on-site cardiac surgery. The six week mortality rate observed was 0.9% at hospitals without on-site surgery and
1% vice versa. The 95% CI for the difference in six-week mortality rate was -0.31 to 0.23 with a p-value of 0.004 for non-
inferiority. The results suggest that PCI performed at hospitals without on-site cardiac surgery was non-inferior to PCI performed
at hospitals with on-site cardiac surgery with respect to mortality at six weeks and major adverse cardiac events at nine months.
However, the 3:1 randomization was not optimized statistically. The optimal randomization ratio is 1.22:1 which is illustrated
in Figure 1 using relative efficiency curve. The computation of optimal allocation for different randomization ratio is illustrtaed
in Figure 1 and Table 1.
Randomization Ratio of Treatment to Control (k:1) Relative Efficiency to Optimal Allocation
0.33 1.48
1.00 1.01
1.22 1.00
3.00 1.21
TABLE 1 Relative efficiencies of different randomization ratio to control (k:1). The loss of efficiency is about 1% with equal
allocation, however with 3:1 randomization ratio, the loss of efficiency increases to 21%. Aversano et al. would have lost more
efficiency if they decided to use 1:3 randomization ratio.
5 DISCUSSION
We have derived optimal allocation for superiority trials with multiple drugs versus control and computed the relative efficiency
compared to a balanced allocation. The optimal allocation is unbalanced in a superiority trial with multiple drugs each compared
to control. Even with superiority trials comparing two binomial endpoints, the optimal randomization is not 1:1 because the
power calculations use the variance of the difference in proportions under the alternative, although this difference is usually
trivial16. In non-inferiority trials, additive margin with equal variance is the only instance with balanced randomization. With
multiplicative margins, 1:1 randomization is less effective because we are estimating a weighted sum and even with additive
margins in non-inferiority trials, variance differs under 퐻0 for example with binary outcomes (binomial) implying optimality
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FIGURE 1 Relative efficiency plot of CPORT trial versus randomization ratio of performing PCI at hospitals with no on-site
cardiac surgery. The optimal randomization ratio is 1.22:1.
FIGURE 2 The tool for sample size calculation for non-inferiority trial with additive or multiplicative margin with normal,
binomial or poisson distribution.
with unbalanced randomization. In survival data, the balanced allocation is only optimal when the hazard ratio is equal to 1
which is unlikely in non-inferiority trials.
As we demonstrated in the earlier sections, it is sometimes optimal to implement an unequal allocation. In designing clinical
trials, the ethical concerns intertwine with proper scientific judgment. Researchers have to be careful and wise in planning a
trial to prevent failure in achieving the primary outcome.
An application for a sample size calculator in a non-inferiority trial with randomization ratio and relative efficiency to balanced
randomization is available at http://www.statlab.wisc.edu/shiny/SSNI/. The sample size calculator computes sample sizes for
multiplicative or additivemargin with normal, binomial or Poisson distribution. The application also reveals other randomization
ratios with their relative efficiency compared to the optimal allocation.
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FIGURE 3 The asymptotic relative efficiency of optimal allocation relative to equal allocation in non-inferiority trial with
multiplicative Δ and equal, unequal variance (small difference in variance), (휎퐶 = 20, 휎푇 = 30) and unequal variance (large
difference in variance) (휎퐶 = 40, 휎푇 = 100), with different Δ’s.
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